This week’s plant medicine newsletter covers CBD’s potential for neuroinflammation and Alzheimer’s disease, new research on CBD for chemotherapy-induced pain, oral health,
This week’s newsletter covers a promising psychedelic therapy pilot study for clinical depression, psilocybin research on dementia and childhood trauma, new findings
This week’s newsletter covers CBD’s potential for addressing digital era fatigue, critical perspectives on psychedelic research and clinical overreach, the case for
This week’s newsletter covers CBD’s potential to reduce Alzheimer’s-related brain inflammation, psilocybin’s promise for pain relief and neurological conditions, cannabis as an
This week’s newsletter covers new research on how cannabis affects brain activity during sleep, promising findings on CBD’s role in pain management
This week’s newsletter covers an Iranian study on CBD bioavailability and delivery methods, critiques of Canada’s cannabis market and flavored vape policy,
This week’s newsletter covers a federally funded study on cannabis access and opioid overdose reduction, the potential of CBD-derived plastics, the risks
This week’s newsletter covers the limited scope of Trump’s cannabis rescheduling announcement, new research on CBD’s potential in wound healing and rheumatoid
This week’s newsletter covers the limits of cannabis rescheduling on federal criminal penalties, the largely symbolic nature of Trump’s psychedelics executive order,
This week’s newsletter covers the latest in plant medicine research, including cannabis’s dual effects on inflammation, CBD’s potential for gut-liver health, pain